Use of serum uPA change to predict PFS and overall survival in first-line trastuzumab-treated breast cancer

被引：0
|
作者：
Hou, H. Y.
Anyanwu, U.
Jamshidi, N.
Leitzel, K.
Ali, S. M.
Koestler, W.
Fuchs, E.
Hamer, P.
Carney, W. P.
Lipton, A.
机构：
[1] Penn State Hershey Med Ctr, Hershey, PA USA
[2] Lebanon VA Med Ctr, Lebanon, PA USA
[3] Med Univ Vienna, Vienna, Austria
[4] Siemens Healthcare Diagnost, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.1050
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1050
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Serum endoglin and uPA change predicts PFS and overall survival in first line trastuzumab-treated breast cancer
    Evans, Matthew S.
    Hou, Hui Ying
    Anyanwu, Uchechi
    Leitzel, Kim
    Ali, Suhail M.
    Koestler, Wolfgang
    Fuchs, Eva-Maria
    Brown-Shimer, Sheryl
    Hamer, Peter
    Carney, Walter
    Lipton, Allan
    CANCER RESEARCH, 2011, 71
  • [2] Pretreatment serum metabolome predicts PFS in first-line trastuzumab-treated metastatic breast cancer
    O'Day, Elizabeth
    Leitzel, Kim
    Ali, Suhail M.
    Zhang, Bo
    Dong, Chen
    Gu, Haiwei
    Shi, Xiajian
    Drabick, Joseph J.
    Cream, Leah
    Vasekar, Monali
    Polimera, Hyma V.
    Nagabhairu, Vinod
    Moku, Prashanth
    Maddukuri, Ashok
    Menon, Harry
    Pancholy, Neha
    Carney, Walter P.
    Koestler, Wolfgang
    Lipton, Allan
    CANCER RESEARCH, 2020, 80 (04)
  • [3] Elevated pretreatment serum biomarkers and correlation with progression-free(PFS) and overall survival (OS) in first-line trastuzumab-treated metastatic breast cancer
    Ali, Suhail M.
    Leitzel, Kim
    Anyanwu, Uchechi
    Hou, Hui Ying
    Evans, Matthew Stephen
    Shrivastava, Vika
    Koeztler, Wolfgang
    Fuchs, Eva-Maria
    Esteva, Francisco J.
    Carney, Walter P.
    Lipton, Allan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Elevated pretreatment serum TIMP-1 level predicts reduced PFS and overall survival in trastuzumab-treated metastatic breast cancer patients
    Anyanwu, Uchechi
    Hou, Hui
    Evans, Matthew
    Kostler, Wolfgang
    Fuchs, Eva-Maria
    Ali, Suhail
    Leitzel, Kim
    Demers, Laurence
    Hamer, Peter
    Pierce, Karen
    Brown-Shimer, Sheryl
    Carney, Walter
    Lipton, Allan
    CANCER RESEARCH, 2009, 69
  • [5] Elevated pretreatment serum activin A and progression-free and overall survival in trastuzumab-treated metastatic breast cancer
    Zubritsky, Lindsey
    Leitzel, Kim
    Ali, Suhail M.
    Kstler, Wolfgang
    Fuchs, Eva-Maria
    Costa, Luis
    Knight, Robert D.
    Laadem, Abderrahmane
    Sherman, Matthew L.
    Lipton, Allan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (30)
  • [6] Elevated pretreatment serum activin A and progression-free and overall survival in trastuzumab-treated metastatic breast cancer.
    Lipton, Allan
    Zubritsky, Lindsey
    Leitzel, Kim
    Ali, Suhail M.
    Koestler, Wolfgang
    Fuchs, Eva-Maria
    Costa, Luis
    Knight, Robert D.
    Laadem, Abderrahmane
    Sherman, Matthew L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Elevated Serum Ferritin Predicts Reduced Progression-Free and Overall Survival in Trastuzumab-Treated Metastatic Breast Cancer.
    Alkhateeb, A. A.
    Connor, J.
    Leitzel, K.
    Ali, S.
    Campbell-Baird, C.
    Evans, M.
    Koestler, W.
    Fuchs, E-M
    Lipton, A.
    CANCER RESEARCH, 2011, 71
  • [8] Relapse impact on overall survival in trastuzumab-treated women with HER2+early-stage breast cancer
    Gallagher, Christopher M.
    More, Kenneth
    Masaquel, Anthony
    Kamath, Tripthi
    Guerin, Annie
    Ionescu-Ittu, Raluca
    Gauthier-Loiselle, Marjolaine
    Nitulescu, Roy
    Wu, Eric Qiong
    Sicignano, Nicholas
    Butts, Elizabeth
    Barnett, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer
    Tate, Sonya C.
    Andre, Valerie
    Enas, Nathan
    Ribba, Benjamin
    Gueorguieva, Ivelina
    EUROPEAN JOURNAL OF CANCER, 2016, 66 : 95 - 103
  • [10] Trastuzumab as first-line therapy for metastatic breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (07) : 776 - 776
12345